In this study, 44 patients with hormone receptor‐positive, HER2‐negative, advanced BC were treated with trabectedin at a dose of 1.3 mg/m2 over 3‐h infusion q3 wk and stratified according to the XPG status (high XPG (>3) or low XPG (≤3)) 82. This evidence concerns the gene ERBB2 and breast cancer.